Stay updated with breaking news from World Bronchiectasis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Electromed, Inc. (AMEX:ELMD) Q4 2023 Earnings Call Transcript August 22, 2023 Operator: Greetings, and welcome to Electromed’s Fourth Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] It is now my pleasure to introduce Mike Cavanaugh, Investor Relations. […]
/PRNewswire/ - Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies...
Inhaled colistimethate sodium showed a large benefit in one trial but produced almost no effect in the other, a result attributed to the COVID pandemic.
Two nonantibiotic strategies are moving forward as possible options for the most difficult NTM pathogens.
Patients with nontuberculous mycobacteria have more lung disease complications at baseline but their outcome at 5 years is almost same as that of patients with bronchiectasis alone.